Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.44 |
| ▸ | NPY1R | P25929 | 6/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320944 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL29532212 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30340047 | 0.97 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL29939543 | 0.95 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30898573 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30716491 | 0.94 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30148421 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30945402 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL29799968 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 | |
| SCHEMBL30456493 | 0.92 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| EP-4566666-A2 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR IX FUNCTION | The Children's Hospital Of Philadelphia (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3490586-B1 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR IX FUNCTION | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4473008-A2 | COMPOSITIONS AND METHODS FOR TREATING FACTOR IX DEFICIENCY | The Children's Hospital Of Philadelphia (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20230250412-A1 | Compositions and Methods for Modulating Factor IX Function | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2023-08-10 | — | — | US | disclosed |
| WO-2023147574-A2 | COMPOSITIONS AND METHODS FOR TREATING FACTOR IX DEFICIENCY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11708570-B2 | Compositions and methods for modulating Factor IX function | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210355473-A1 | CHIMERIC CLOTTING FACTORS | BIOVERATIV THERAPEUTICS INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-10968442-B2 | Chimeric clotting factors | BIOVERATIV THERAPEUTICS INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-2591099-B1 | CHIMERIC CLOTTING FACTORS | BIOVERATIV THERAPEUTICS INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20020192794-A1 | Purification of plasmin; obtain sample of plasminogen, incubate with activator, recover plasmin | GRIFOLS INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1232252-A1 | REVERSIBLY INACTIVATED ACIDIFIED PLASMIN | Bayer Corporation (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1232254-A1 | PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION | Bayer Corporation (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036611-A1 | PROCESS FOR THE PRODUCTION OF A REVERSIBLY INACTIVE ACIDIFIED PLASMIN COMPOSITION | BAYER CORPORATION (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001036608-A1 | REVERSIBLY INACTIVATED ACIDIFIED PLASMIN | BAYER CORPORATION (US) | 2001-05-25 | — | — | WO | disclosed |
| US-5407673-A | Fibrinolysis and fibrinogenolysis treatment | ORION THERAPEUTIC SYSTEMS, INC. (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0620738-A1 | FIBRINOLYSIS AND FIBRINOGENOLYSIS TREATMENT WITH PLASMIN | ORION THERAPEUTIC SYSTEMS, INC. (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5288489-A | Fibrinolysis and fibrinogenolysis treatment | ORION THERAPEUTIC SYSTEMS, INC. (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1993007893-A1 | FIBRINOLYSIS AND FIBRINOGENOLYSIS TREATMENT WITH PLASMIN | ORION THERAPEUTIC SYSTEMS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968442-B2 | Chimeric clotting factors | F13B, F11, F3 | NPY4R 3649/4885NPY1R 3979/4885NPY2R 4156/4885 |
| US-20210355473-A1 | CHIMERIC CLOTTING FACTORS | F13B, F11, F3 | NPY4R 3649/4885NPY1R 3979/4885NPY2R 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.